Taro Pharmaceutical Industries Ltd.
TARO
TARO was delisted on the 21st of June, 2024.
159 hedge funds and large institutions have $1.02B invested in Taro Pharmaceutical Industries Ltd. in 2016 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 84 increasing their positions, 33 reducing their positions, and 31 closing their positions.
485% more call options, than puts
Call options by funds: $6.99M | Put options by funds: $1.19M
155% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 33
24% more capital invested
Capital invested by funds: $829M → $1.02B (+$196M)
5% less funds holding
Funds holding: 167 → 159 (-8)
16% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 31
38% less funds holding in top 10
Funds holding in top 10: 8 → 5 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$40.6M |
| 2 |
Schroder Investment Management Group
London,
United Kingdom
|
+$20.1M |
| 3 |
Renaissance Technologies
New York
|
+$18.4M |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$15.2M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$14.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCM
Greywolf Capital Management
Purchase,
New York
|
-$35.1M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
-$8.62M |
| 3 |
GPC
Guardian Point Capital
Charlottesville,
Virginia
|
-$7.16M |
| 4 |
Morgan Stanley
New York
|
-$5.21M |
| 5 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
-$4.5M |
TARO Hedge Fund Activity: Q2 2016 in Review
159 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Taro Pharmaceutical Industries Ltd. (TARO) for Q2 2016, worth a combined $1.02B — up 24% from $829M a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of TARO and 26 opened new positions — a net loss of 5 holders — while 33 trimmed existing stakes and 84 added.
The largest buyer was Goldman Sachs, adding an estimated $40.6M. The largest seller was Greywolf Capital Management, exiting entirely with an estimated $35.1M sold.
- 159 institutional investors held Taro Pharmaceutical Industries Ltd. (TARO) as of Q2 2016, down from 167 in Q1 2016.
- Funds reported $1.02B of Taro Pharmaceutical Industries Ltd. stock for Q2 2016, up 24% quarter-over-quarter.
- 26 funds opened new Taro Pharmaceutical Industries Ltd. positions in Q2 2016 and 31 closed out, a net change of -5 holders.
- The largest Taro Pharmaceutical Industries Ltd. buyer in Q2 2016 was Goldman Sachs, an estimated $40.6M added.
- The largest Taro Pharmaceutical Industries Ltd. seller in Q2 2016 was Greywolf Capital Management, an estimated $35.1M sold.
Based on aggregated 13F filings for Q2 2016.